Appointments at BioDelivery Sciences, SOCMA and Sanofi-aventis – People on the move

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at BioDelivery Sciences, SOCMA and Sanofi-aventis.

BioDelivery Sciences has hired Steven Dykstra as senior vice president (SVP) of manufacturing operations. Dykstra has 29 years of pharma manufacturing experience working at companies including IVX Animal Health/Teva, MGI Pharma and DuPont Merck Pharmaceuticals.

Shawn Cavanagh has been named EVP and chief operating officer (COO) at Cambrex. Cavanagh worked at Cambrex Bioproducts when it was acquired by Lonza in 2007. Since then Cavangh has worked at Lonza but has now rejoined Cambrex to oversee contract manufacturing.

Ampac Fine Chemicals president Aslam Malik has joined the Society of Chemical Manufacturers and Affiliates (SOCMA) board of directors. Malik has been president of Ampac Fine Chemicals since 2005 and has 24 years of industrial experience in fine chemical scale-up.

Shailesh Shah has been promoted to president and CEO of SOHM’s US, Indian and global operations. Shah was formerly VP for corporate strategy at SOHM.

Sanofi-aventis has made three appointments to strengthen management in emerging markets. Patrick Aghanian is now head of the Eurasia region, Thomas Kelly was named head of the Asia region and Heraldo Marchezini will head operations in Latin America.

Gregory Papaz has joined Optimer Pharmaceuticals as SVP of commercial operations. Papaz has previously worked at Genentech, Roche and Sanofi-Aventis.

Cevec has revamped its supervisory board, with Rainer Christine, CEO and co-founder of amaxa, joining and Gangolf Ehlen, the former chairman, departing to pursue a role at Sparkasse KölnBonn. Karlheinz Schmelig is the new chairman of the board.

Alex Gorsky, worldwide chairman of medical devices and diagnostics, and Sheri McCoy, worldwide chairman of pharmaceuticals, have been appointed vice chairmen of the executive committee at Johnson & Johnson.

Crescendo Biologics has appointed Mike Romanos as CEO. Romanos has served as chief scientific officer since May 2009 having previously worked at GlaxoSmithKline.

Arlene Morris is to step down as CEO of Affymax and be replaced by John Orwin. Orwin is currently president and COO of Affymax and will now replace Morris as CEO and on the board. Morris will work as a consultant to Affymax until September.